您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8520 处方药 8144 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 神经系统药物->催眠药物
处方药:处方药
包装规格: 30片/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
默克公司
生产厂家英文名:
Merck Sharp & Dohme LLC
该药品相关信息网址1:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5b72731-1acb-45b7-9c13-290ad12d3951
该药品相关信息网址2:
https://www.belsomra.com/
原产地英文商品名:
Belsomra® (suvorexant) tablets CIV 10 mg *30 Tablets
原产地英文药品名:
suvorexant
中文参考商品译名:
Belsomra® 片剂CIV 10毫克*30片
中文参考药品译名:
苏沃雷生
原产地国家批准上市年份:
2014/08/29
英文适应病症1:
insomnia
临床试验期:

中文适应病症参考翻译1:
失眠症
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件(20237321304821.pdf)文件为准
---------------------------------------------------------------
部分中文 处方资料(仅供参考)



【适应症】用于治疗失眠症。

苏沃雷生属于增强自然睡意的安眠药。 一般降低脑机能的安眠药主要是抑制作用于觉醒工作的神经活动,促进睡意。制造【疲劳发困】的相近状态,是一种强迫式的效果。因此,被称作睡眠导入剂。 苏沃雷生类增强自然睡意的安眠药是调整与我们的睡眠和觉醒周期相关的生理性物质的运作,导向睡眠状态的一种药。是增强原有的困意的一种形态,效果因人而异。



Belsomra (suvorexant)


  Suvorexant, sold under the trade name Belsomra, is a medication for the treatment of insomnia. It is effective for insomnia, at least for four weeks and as compared to a placebo.  


  Suvorexant is a selective, dual orexin receptor antagonist (DORA) made by Merck & Co. It was approved for sale by the U.S. Food and Drug Administration (FDA) on August 13, 2014.The U.S. Drug Enforcement Administration (DEA) has placed it on the list of schedule IV controlled substances,]as it may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III. The potential for psychological dependence is similar to that of zolpidem.  


  The drug was initially released November 2014 in Japan, then later reached the United States in February 2015and Australia in November 2016.

 

Medical uses  


  Suvorexant is used for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.  


  It is unclear how the medication compares to others used for insomnia as no comparisons have been done.It is also unclear if this medication is safe among people with a history of addiction, as they were excluded from the clinical trials of suvorexant.

 

Contraindications  


  This drug is not recommended in people with liver impairment.Suvorexant pregnancycategory is currently classified as Category C. Based on animal testing, this medication may cause fetal harm during pregnancy and should only be given in pregnancy if the potential benefit justifies the potential harm to the fetus. Evidence is inconclusive about whether using this medication while breastfeeding puts the infant at risk of harm.  


  Suvorexant is contraindicated in people diagnosed with narcolepsy.

 

Mechanism of action


  Suvorexant exerts its therapeutic effect in insomnia through antagonism of orexin receptors. The orexin neuropeptide signaling system is a central promoter of wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors orexin receptor type 1 (OX1) and orexin receptor type 2 (OX2) is thought to suppress wake drive.Animal studies report the binding affinities for OX1 (0.55 nM) and OX2 (0.35 nM).

---------------------------------------------------------------
 详细处方信息以本药内容附件(20237321304821.pdf)文件为准
---------------------------------------------------------------

更新日期: 20230704
附件:
20237321304821.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com